Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IOVA - US4622601007 - Common Stock

2.4474 USD
+0.01 (+0.3%)
Last: 11/28/2025, 12:28:26 PM
Fundamental Rating

2

IOVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of IOVA have multiple concerns. IOVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IOVA had negative earnings in the past year.
In the past year IOVA has reported a negative cash flow from operations.
IOVA had negative earnings in each of the past 5 years.
In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

IOVA has a Return On Assets (-43.94%) which is comparable to the rest of the industry.
IOVA has a Return On Equity of -56.62%. This is in the better half of the industry: IOVA outperforms 62.85% of its industry peers.
Industry RankSector Rank
ROA -43.94%
ROE -56.62%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA has a Gross Margin of 23.96%. This is in the better half of the industry: IOVA outperforms 72.61% of its industry peers.
The Profit Margin and Operating Margin are not available for IOVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 23.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

3

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IOVA has been increased compared to 1 year ago.
The number of shares outstanding for IOVA has been increased compared to 5 years ago.
Compared to 1 year ago, IOVA has an improved debt to assets ratio.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IOVA has an Altman-Z score of -2.36. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
IOVA has a Altman-Z score (-2.36) which is comparable to the rest of the industry.
IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, IOVA perfoms like the industry average, outperforming 50.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.36
ROIC/WACCN/A
WACC8.63%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

IOVA has a Current Ratio of 3.41. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
IOVA has a Current ratio (3.41) which is in line with its industry peers.
IOVA has a Quick Ratio of 3.00. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
IOVA has a Quick ratio of 3.00. This is in the lower half of the industry: IOVA underperforms 60.98% of its industry peers.
Industry RankSector Rank
Current Ratio 3.41
Quick Ratio 3
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.13% over the past year.
The Revenue has grown by 175.62% in the past year. This is a very strong growth!
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%

3.2 Future

The Earnings Per Share is expected to grow by 20.28% on average over the next years. This is a very strong growth
Based on estimates for the next years, IOVA will show a very strong growth in Revenue. The Revenue will grow by 42.64% on average per year.
EPS Next Y10.2%
EPS Next 2Y22.64%
EPS Next 3Y21.86%
EPS Next 5Y20.28%
Revenue Next Year63.25%
Revenue Next 2Y60.84%
Revenue Next 3Y54.95%
Revenue Next 5Y42.64%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 21.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.64%
EPS Next 3Y21.86%

More info and screens

0

5. Dividend

5.1 Amount

IOVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (11/28/2025, 12:28:26 PM)

2.4474

+0.01 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners61.39%
Inst Owner Change-3.46%
Ins Owners0.36%
Ins Owner Change6.84%
Market Cap885.59M
Revenue(TTM)250.43M
Net Income(TTM)-397.63M
Analysts75.56
Price Target7.91 (223.2%)
Short Float %28.77%
Short Ratio6.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-13.7%
Max EPS beat(2)8.8%
EPS beat(4)2
Avg EPS beat(4)-11.94%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.8%
EPS beat(8)5
Avg EPS beat(8)-4.19%
EPS beat(12)9
Avg EPS beat(12)3.75%
EPS beat(16)11
Avg EPS beat(16)2.89%
Revenue beat(2)0
Avg Revenue beat(2)-12.22%
Min Revenue beat(2)-15.78%
Max Revenue beat(2)-8.66%
Revenue beat(4)0
Avg Revenue beat(4)-16.36%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)-0.2%
Revenue beat(8)2
Avg Revenue beat(8)-20.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.84%
PT rev (3m)-14.84%
EPS NQ rev (1m)5.05%
EPS NQ rev (3m)6.43%
EPS NY rev (1m)-1.94%
EPS NY rev (3m)-2.61%
Revenue NQ rev (1m)-3.25%
Revenue NQ rev (3m)-2.83%
Revenue NY rev (1m)-1.78%
Revenue NY rev (3m)-1.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.54
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-1.19
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.69
BVpS1.94
TBVpS1.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.94%
ROE -56.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 23.96%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 76.09%
Cap/Sales 11.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.41
Quick Ratio 3
Altman-Z -2.36
F-Score4
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y10.2%
EPS Next 2Y22.64%
EPS Next 3Y21.86%
EPS Next 5Y20.28%
Revenue 1Y (TTM)175.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.2%
Revenue Next Year63.25%
Revenue Next 2Y60.84%
Revenue Next 3Y54.95%
Revenue Next 5Y42.64%
EBIT growth 1Y6.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.88%
EBIT Next 3Y17.85%
EBIT Next 5YN/A
FCF growth 1Y6.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.11%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ

What is the fundamental rating for IOVA stock?

ChartMill assigns a fundamental rating of 2 / 10 to IOVA.


Can you provide the valuation status for IOVANCE BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (IOVA). This can be considered as Overvalued.


Can you provide the profitability details for IOVANCE BIOTHERAPEUTICS INC?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a profitability rating of 1 / 10.


What is the expected EPS growth for IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

The Earnings per Share (EPS) of IOVANCE BIOTHERAPEUTICS INC (IOVA) is expected to grow by 10.2% in the next year.